Skip to content
lifestyle.longislandreport.org
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Whitehawk Therapeutics
Whitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026
September 13, 2026
Whitehawk Therapeutics Appoints Vijay Iyengar, MD, to Board of Directors
September 10, 2026
Whitehawk Therapeutics to Participate in Upcoming Investor Conferences
September 2, 2026
Whitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
August 6, 2026
Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026
May 30, 2026
Whitehawk Therapeutics to Present at the Jefferies 2026 Global Healthcare Conference
May 28, 2026
Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload
May 21, 2026
Whitehawk Therapeutics Presents Comprehensive Preclinical Data Highlighting its Next-Generation ADC Portfolio at the AACR 2026
April 19, 2026
Whitehawk Therapeutics to Participate in Jones Trading Post-AACR Fireside Chat Series
April 16, 2026
Whitehawk Therapeutics Presents Real-World Analysis Confirming MUC16 as a Highly Expressed, Clinically Relevant Target for Gynecologic Cancers at SGO 2026
April 10, 2026